Patents by Inventor Anne Rogel

Anne Rogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230192845
    Abstract: Provided is a CD96-binding agent, wherein the agent is capable of stimulating activation and/or proliferation of T cells upon binding to CD96. Also provided are isolated nucleic acids and cells that produce the agent and uses thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: June 22, 2023
    Applicants: BLINK BIOMEDICAL SAS, TALIX THERAPEUTICS NV
    Inventors: Florence Renart-Depontieu, Sachiko Takami, Germain Margall-Ducos, Nicola Beltraminel-Li, Pierre Garrone, Anne Rogel, Aymen Al-Shamkhani, Xavier Preville
  • Patent number: 9573975
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: February 21, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, François Lang, Mathilde Bobinet, Anne Rogel
  • Patent number: 9475841
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 25, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Publication number: 20150291660
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: October 15, 2015
    Applicants: UNIVERSITE D'ANGERS, INSERM (INSSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Publication number: 20150132329
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 14, 2015
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel